Volume 6.02 | Jan 23

Prostate Cell News 6.02 January 23, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
Endostatin: A Novel Inhibitor of Androgen Receptor Function in Prostate Cancer
Scientists report a profound effect of endostatin on prostate cancer cells by efficient intracellular trafficking, direct interaction with androgen receptor (AR), reduction of nuclear AR level, and down-regulation of AR-target gene transcription. [Proc Natl Acad Sci USA] Abstract
Listen Now: Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by impact factor of the journal)

Cytotoxicity of Obacunone and Obacunone Glucoside in Human Prostate Cancer Cells Involves Akt-Mediated Programmed Cell Death
Scientists report the mechanism of cytotoxicity of citrus-derived obacunone and obacunone glucoside on human androgen-dependent prostate cancer LNCaP cells. [Toxicology] Abstract

Ginkgetin Inhibits the Growth of DU-145 Prostate Cancer Cells through Inhibition of STAT3 Activity
Ginkgetin inhibited both inducible and constitutively activated signal transducer and activator of transcription 3 (STAT3) and blocked the nuclear translocation of p-STAT3 in DU-145 prostate cancer cells. [Cancer Sci] Abstract

Androgen-Regulation of the Protein Tyrosine Phosphatase PTPRR Activates ERK1/2 Signaling in Prostate Cancer Cells
Characterisation of PTPRR protein in LNCaP cells revealed it is an early and direct target of the androgen receptor which negatively regulates the RAS/ERK1/2 pathway and reduces cell proliferation in response to androgens. [BMC Cancer]
Full Article

Downregulation of EphA5 by Promoter Methylation in Human Prostate Cancer
Researchers investigated the expression and an epigenetic change of EphA5 in prostate cancer and determined if these findings were correlated with clinicopathologic characteristics of prostate cancer. [BMC Cancer] Abstract | Full Article

MAPK and JAK/STAT Pathways Targeted by miR-23a and miR-23b in Prostate Cancer: Computational and In Vitro Approaches
MAPK and JAK/STAT pathways are known to have essential roles in cell proliferation and neoplastic transformation in different cancers including prostate cancer. Scientists aimed to identify microRNAs (miRNAs) that target these pathways in the context of prostate cancer as therapeutic molecules. They then analyzed the expression of candidate miRNAs in LNCAP and PC3 cell lines as well as prostate cancer clinical samples. [Tumor Biol] Abstract

Cycloartan-24-Ene-1α,2α,3β-Triol, a Cycloartane-Type Triterpenoid from the Resinous Exudates of Commiphora myrrha, Induces Apoptosis in Human Prostatic Cancer PC-3 Cells
Researchers isolated a cycloartane triterpenoid from Commiphora myrrha and evaluated its anticancer potential. Cycloartan-24-ene-1α,2α,3β-triol showed cytotoxic activity on PC-3 cells in a concentration-dependent manner with an IC50 value of 9.6 µM at 24 hours. [Oncol Rep] Abstract

Proapoptotic Effect of Endocannabinoids in Prostate Cancer Cells
Researchers aimed to detect the presence of cannabinoid receptors on cancer cells with a prostatic origin and evaluated the effect of the in vitro use of synthetic analogs. [Oncol Rep] Abstract | Download Full Article

Peperotetraphin Inhibits the Proliferation of Human Prostate Cancer Cells via Induction of Cell Cycle Arrest and Apoptosis
Peperotetraphin is a novel cyclobutane-type norlignan, which was isolated from the whole plant of Peperomia tetraphylla. Scientists explored its anti-tumor effect and the molecular mechanism in human prostate cancer PC-3 cell lines. [Med Oncol] Abstract


Abiraterone Acetate plus Prednisone versus Placebo plus Prednisone in Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer (COU-AA-302): Final Overall Survival Analysis of a Randomized, Double-Blind, Placebo-Controlled Phase III Study
The authors present the prespecified final analysis of the COU-AA-302 trial, assessing the effect of abiraterone acetate plus prednisone on overall survival, time to opiate use, and use of other subsequent therapies. [Lancet Oncol] Abstract

Activity of Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer Is Affected by Prior Treatment with Abiraterone and/or Docetaxel
Investigators examined the response and outcomes of enzalutamide-treated metastatic castration-resistant prostate cancer patients in the real-world context of prior treatments of abiraterone and/or docetaxel. [Prostate Cancer Prostatic Dis] Abstract

FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours
Clinical Significance of ERβ in Breast and Prostate Cancer from Biological Aspects
The function of estrogen receptor (ER)β been investigated using a variety of methods and biological systems, leading to the present understanding that ERβ can interact with or inhibit ERα and androgen receptor function directly and/or indirectly, suppress cell growth, and influence responsiveness to endocrine therapy. [Cancer Sci] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Cleveland Clinic Receives $1 Million For Prostate Cancer Research
The Prostate Cancer Foundation has presented Nima Sharifi, M.D., Kendrick Family Chair for Prostate Cancer Research at Cleveland Clinic, a Challenge Award to advance the treatment of lethal prostate cancer. He is also co-investigator on a second Challenge Award that was also selected for funding. [Cleveland Clinic]
Press Release

New Animal Models Faithfully Reproduce the Tumor of Each Patient
A team from the Catalan Institute of Oncology and Bellvitge Biomedical Research Institute has developed new animal models that reproduce faithfully the evolution and malignancy of different human tumors. [Bellvitge Biomedical Research Institute] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cellular Therapy 2015 – 8th International Symposium on the Clinical Use of Cellular Products
March 19-20, 2015
Erlangen, Germany

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Researcher – Prostate Cancer (Spanish National Cancer Research Centre [CNIO])

NEW Postdoctoral Researcher – Prostate Cancer (University of Pennsylvania)

Director (California Institute for Regenerative Medicine)

Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

Postdoctoral Fellow – Prostate Cancer Epigenetics and Genomics (UT Southwestern)

PhD Studentship – Chemokine Receptor in Prostate Cancer Metastasis (University of East Anglia)

Postdoctoral Research Associate Positions – Cancer Biology (Hollings Cancer Center)

Research Technologist – Media Development (STEMCELL Technologies Inc.)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us